Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration
ConclusionSwitching to brolucizumab in eyes refractory to aflibercept conferred favorable outcomes in controlling exudative changes. However, IOI and the regulation of the treatment interval to at least 8 weeks during the maintenance phase disrupted the continuation of brolucizumab treatment.
Source: Japanese Journal of Ophthalmology - Category: Opthalmology Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Eyes | Japan Health | Opthalmology | Study | Vitamin A